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NrCAM (neuron-glia-related cell-adhesion molecule) is primarily, although not solely, expressed in the nervous system. In the present
study, NrCAM expression was analysed in a series (46) of papillary thyroid carcinomas (PTCs) and paired normal tissues (NT).
Quantitative reverse transcriptase (QRT)-PCR revealed that NrCAM expression was upregulated in all PTCs compared to normal
thyroid, whatever the stage or size of the primary tumour. NrCAM transcript levels were 1.3- to 30.7-fold higher in PTCs than in NT.
Immunohistochemistry (IHC) confirmed that the expression of NrCAM was considerably higher in tumours (score 2þ/3þ) than in
adjacent normal paratumoural thyroid tissue. The NrCAM protein was detected in all but three (93.3%) PTC samples, and it was
mainly cytoplasmic; in some cases there was additional membranous localisation – basolateral and partly apical. In the normal thyroid
and tissues surrounding tumours, focal NrCAM immunolabelling was seen only in follicles containing tall cells, where staining was
restricted to the apical pole of thyrocytes. Western blot analysis corroborated the QRT–PCR and IHC results, showing higher
NrCAM protein levels in PTCs than in paired NT. The level of overexpression of the NrCAM mRNA in tumourous tissue appeared
to be independent of the primary tumour stage (pT) or the size of the PTC. These data provide the first evidence that NrCAM is
overexpressed in human PTCs at the mRNA and protein levels, whatever the tumour stage. Thus, the induction and upregulation of
NrCAM expression could be implicated in the pathogenesis and behaviour of papillary thyroid cancers.
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Thyroid tumours are the most frequent malignancies of the
endocrine system (DeLellis and Williams, 2004). The most
common type is papillary thyroid carcinoma (PTC), a well-
differentiated tumour that accounts for 80–90% of all thyroid
malignancies. The early stages of PTC development appear to be
the consequence of abnormal genetic alteration of several proto-
oncogenes, growth factor receptors, and tumour suppressor genes
(Santoro et al, 2002; Tallini, 2002; Nikiforova et al, 2003). The most
common genetic abnormalities associated with papillary thyroid
carcinomas (PTCs) are activating mutations in BRAF, the gene for
the B-type serine-thereonine kinase RAF, identified from 29 to
83% of patients, and RET/PTC rearrangements detected much less
frequently in adult PTCs (Kimura et al, 2003; Namba et al, 2003;
Soares et al, 2003; Kim et al, 2004; Santoro et al, 2004; Xing, 2005;
Trovisco et al, 2006). In a variety of malignancies, tumour
progression is associated with changes in cell adhesion, which
affect the biological characteristics and behaviour of the cancer
(Christofori, 2003; Ezzat and Asa, 2005). Cell-adhesion molecules
(CAMs), belonging to the L1 family within the immunoglobulin-
like superfamily, are cell-surface glycoproteins predominantly but
not exclusively expressed in the peripheral and central nervous
system where they mediate different aspects of neuronal tissue
development (Suter et al, 1995; Sakurai et al, 2001; Falk et al, 2004;
Zelina et al, 2005). These proteins contain multiple C2-type
immunoglobulin (Ig)-like extracellular domains and multiple
fibronectin type III (FnIII) repeats, which are connected with the
cell membrane via a transmembrane domain or lipid anchor
(Williams and Barclay, 1988; Gumbiner, 1996; Hortsch, 2000). The
NrCAM (neuron-glia-related cell-adhesion molecule) is a 200–
220kDa transmembrane protein composed of six Ig-like domains
and five FnIII repeats in the extracellular region, plus a highly
conserved cytoplasmic tail (Grumet et al, 1991; Kayyem et al, 1992;
Lane et al, 1996). In addition to the nervous system, expression of
the NrCAM gene (chromosome 7q31.1–q31.2) has also been
demonstrated in a variety of healthy or neoplastic tissues and cell
lines including pancreatic cancer, melanoma, renal and colon
carcinoma, adrenal gland, placenta, thyroid, and testis (Wang et al,
1998; Dhodapkar et al, 2001; Conacci-Sorrell et al, 2002a). Recent
reports have linked NrCAM expression with metastatic processes
in particular human cancers (Sehgal et al, 1998; Conacci-Sorrell
et al, 2002b). Gene-expression profiling of PTCs using DNA
microarrays showed that genes encoding adhesion molecules occur
within the set of genes exhibiting differential expression in normal
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sand cancerous thyroid tissues (Jarzab et al, 2005). At present, there
is no information concerning the expression of NrCAM (gene or
protein), its cellular localisation and distribution, or its role in the
evolution of thyroid papillary carcinomas. The aim of this study
was to examine the expression of this adhesion molecule by
analysing both transcript and protein levels in a series of PTCs/
paired normal tissues, and to investigate the association of NrCAM
expression with tumour grade and stage.
MATERIALS AND METHODS
Patients and tissue specimens
Samples of thyroid tumour (n¼46; 100–450mg) were obtained
from 37 women and 9 men (mean age 47.3 years; range 15–74)
being treated at the Maria Sklodowska-Curie Memorial Cancer
Centre and Institute of Oncology in Warsaw and Gliwice, and the
Department of Pathology of the Medical Centre for Postgraduate
Education in Warsaw. Histological examination was used to classify
the tumours as PTCs according to WHO criteria (DeLellis and
Williams, 2004). Healthy tumour-free tissues were also excised from
each individual and processed in parallel. All tissue samples were
immediately frozen in liquid nitrogen and stored at  801Cu n t i lt h e y
were used for quantitative reverse transcription (QRT)–PCR and
protein analysis. For RNA isolation, the cancerous tissue was
separated from the surrounding normal thyroid fragments following
expert guidance from a pathologist. The clinicopathological features
of the thyroid tumours (fresh tissues) are shown in Table 1.
For immunohistochemical analysis, archived formalin-fixed,
paraffin-embedded tissues from patients who underwent surgery
(total thyroidectomy) were used. Tumour staging was carried out
according to the TNM (tumour, node, metastases) staging system.
Fifty-three tumours, including 46 PTCs and 7 follicular adenomas
(3 typical and 4 atypical) were studied. Papillary carcinomas (n¼46)
were subdivided into typical papillary carcinomas (PTC, n¼40) and
follicular variants of papillary carcinomas (FVPTC, n¼6). A total of
28 papillary carcinomas had a papillary growth pattern and 12 had
a mixed papillary-follicular growth pattern. Tumour staging and
NrCAM immunoreactivity are shown in Table 2.
The local human study ethical committees approved this study,
and all patients gave their informed consent.
Quantitative (real-time) RT–PCR analysis
RNA was isolated from frozen thyroid tissues using an RNeasy
Mini Kit (Qiagen, Hilden, Germany). The concentration of specific
NrCAM transcript was quantified by RT (reverse transcriptase)
real-time PCR. Purified total RNA (2mg) was reverse transcribed
using SuperScript II RT (Invitrogen, Carlsbad, CA, USA) primed
with random hexamers in a final volume of 20ml according to the
manufacturer’s protocol. Real-time PCR was carried out using the
double-stranded DNA-specific dye SYBR Green I. The reaction
mixtures contained template cDNA, 12.5ml 2X SYBR Green PCR
Master Mix (PE Applied Biosystems, Foster City, CA, USA), and
50nM primers (listed below) in a final volume of 25ml (Mikula
et al, 2003; Skubis-Zegadło et al, 2005). Amplification, data
acquisition, and data analysis were carried out using the GeneAmp
7000 Sequence Detection System (PE Applied Biosystems).
NrCAM (NM_005010)
Forward: 50-TTGTGCAAAGAGGGAGCATG-30,
Reverse: 50-GGGCAGTTCCCTGTTGTCCT-30,
Melt curves were generated after each run to confirm
the specificity of the amplification reaction. The nature of the
RT–PCR products was additionally verified by agarose gel
electrophoresis. Normalisation of transcript levels to those of the
housekeeping genes GAPDH and b-actin gave similar results.
Polymerase chain reaction amplification efficiencies of the NrCAM
gene, GAPDH, and b-actin genes were as follow: ENrCAM¼1.95,
EGAPDH¼1.96, Eb actin¼1.96.
Rearrangements of RET/PTC1 and RET/PTC3 were analysed by
the real-time PCR using a specific TaqMan probe and reaction
conditions as described previously (Rhoden et al, 2004). The
reaction mixtures contained 5ml cDNA, 12.5ml2  TaqMan PCR
Master Mix and 200nM primers plus 100nM of probe in a final
volume of 25ml. All reactions were carried out in duplicate using
the ABI 7000 system (PE Applied Biosystems). No template
controls were included in each run.
Immunohistochemistry
Sections were prepared from the blocks of tumour tissue. Slices of
3–4mm were dewaxed, deparaffinised, rehydrated, and pretreated
for antigen retrieval by exposure to 0.01% protease XXIV solution
Table 1 Tumour to normal tissue mRNA ratio in relation to
clinicopathologic features of the papillary tumours
Stage No. Patient Sex/Age Histology TNM T/N
T1 1 GD F/36 PTC T1bN1bMo 9.28
2 MT F/44 PTC T1bNoMo 11.49
3 OJ F/51 PTC T1N1Mo 2.43
4 MT M/43 PTC T1NoMo 8.06
5 KM F/51 PTC T1NoMo 9.56
6 ND F/32 PTC T1bNxMx 2.10
7 KB F/44 PTC T1NxMo 3.13
8 PM F/45 PTC T1aNxMx 1.27
9 TM F/46 PTC T1aNoMo 5.10
T2 10 ZM F/35 PTC T2bN1Mo 2.55
11 KB F/58 PTC T2NoMx 2.25
12 PB F/ PTC T2bNoMo 5.56
13 SM M/ PTC T2N1M1 5.16
14 MM F/17 PTC T2N1M1 5.13
15 JS M/52 PTC T2N1Mo 2.12
16 KK F/9 FVPTC T2N1Mo 2.01
17 SE F/43 PTC T2N1Mo 7.32
18 RT F/48 FVPTC T2NoMo 1.12
19 KE F/23 PTC T2NoMo 3.16
20 CA F/ PTC T2NoMo 1.33
21 SP F/15 PTC T2NoMo 5.08
22 MZ F/60 PTC T2NoMo 2.96
23 JM F/69 PTC T2NoMo 9.27
24 KJ F/46 PTC T2NoMo 6.87
25 SH F/32 PTC T2NoMo 8.41
26 JJ F/64 PTC T2NoMo 3.08
27 WB F/50 PTC T2NoMx 1.12
28 DJ F/57 PTC T2NxMo 7.29
29 BT F/59 PTC T2N1Mo 2.93
30 JM M/27 PTC T2NoMo 2.59
31 ZJ F/60 PTC T2NoMo 2.64
32 CT F/ PTC T2NoMo 1.31
T3/T4 33 CT F/ PTC T3N1Mo 3.05
34 SI F/18 PTC T3bN1Mo 5.11
35 HH F/45 FVPTC T4bN1bMx 5.03
36 NK F/58 PTC T4bN1M1 1.15
37 DB F/60 PTC T4bN1Mo 30.37
38 ZG F/71 PTC T4bNoMo 2.92
39 ZJ F/69 FVPTC T4bNxMo 5.91
40 WK F/64 PTC T4N1M1 5.78
41 PM F/74 PTC T4N1Mo 1.35
42 CE F/68 PTC T4NoMo 9.68
43 MJ F/49 PTC T4NoMo 1.33
44 KD M/16 PTC T4N1bM1 2.01
45 SE M/ PTC T3N1M1 15.82
46 ND F/49 PTC TxNoMo 30.75
Abbreviation: TNM¼tumour, node, metastases.
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s(Sigma, Steinheim, Germany) at 371C for 10min. After endogenous
peroxidase activity quenching, and blocking of non-specific
binding, sections were incubated with polyclonal goat anti-NrCAM
antibody (1:200, clone sc-18960 – epitope mapped to an internal
region of NrCAM; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or rabbit polyclonal antibody (1:600, ab24344, directed
against the extracellular NrCAM domain, aa 834–856; Abcam,
Cambridge, UK) overnight at 41C in a humid chamber, followed by
incubation with LSABþdetection kit reagents (DAKO A/S
Glostrup, Denmark), for 15min at room temperature. Between
steps, slides were washed in Tris-buffered saline. Immunoreaction
was visualised with 3, 30-diaminobenzidine (DAB, DAKO) and
nuclei were counterstained with haematoxylin. To ensure antibody
specificity, consecutive sections were incubated in the absence of
primary antibody or with the primary polyclonal goat antibody
that had been preincubated with blocking peptide (peptide
sc-18960P, Santa Cruz), and both of these controls produced no
immunostaining. The staining intensity was graded using a semi-
quantitative score: 0 (no staining), 1 (slight staining), 2 (moderate
staining), 3 (intense staining), and the proportion of positive cells
was scored as 1þ (o10% of cells), 2þ (10–50% of cells), or 3þ
(450% of cells).
Western blot analysis
Samples of approximately 100–450mg of frozen thyroid tissue
were homogenised in an ice-cold buffer (250mM sucrose; 20mM
Tris-HCl, pH 7.4;. 1mM ethylene diamine tetra-acetic acid (EDTA)
containing a cocktail of protease inhibitors (Roche diagnostics
GmbH, Mannheim, Germany) and then centrifuged at 100000g
for 1h. The supernatants were aliquoted and stored at  801C. The
pellets, representing particulate fractions, were resuspended in
20mM Tris-HCl, pH 7.4 containing 1mgml
 1 PMSF (phenyl-
methyl-sulphonyl fluoride), 0.5% Nonidet-P40 and 0.1% Tween-20
and stored at  801C. Protein concentrations in these suspensions
were determined with the BCA protein assay (Pierce Chemical Co,
Rockford, IL, USA) using the manufacturer’s ‘microwell’ protocol.
An equal amount (50mg) of protein extract prepared from each
tissue specimen was mixed with sodium dodecyl sulphate (SDS)
sample buffer (0.25mM Tris-HCl, pH 6.8; 20% glycerol; 4% SDS;
0.1% bromophenol blue), boiled for 3min, separated on 6% SDS–
polyacrylamide gel electrophoresis (PAGE) gels and electroblotted
onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad
Laboratories, Hercules, CA, USA). After blocking, membranes
were incubated overnight at 41C with goat (1:2000, sc-18960, Santa
Cruz) or rabbit (1:2000, ab24344, Abcam) polyclonal antibodies
against NrCAM followed by reaction with horseradish peroxidase-
conjugated affinity-purified secondary antibodies (1:20,000, Jack-
son ImmunoResearch Laboratories, West Grove, PA, USA) for 1h
at room temperature. Between steps, membranes were intensively
washed in PBS-Tween20. Immunostained bands were detected by
the chemiluminescent method using a SuperSignal West Pico
staining kit (Pierce Chemical Co.). Western blot signals were
scanned and quantified using KODAK 1D Image Analysis software
(Eastman Kodak Co. Rochester, NY, USA). The size of reactive
bands was determined by comparison with prestained protein
markers (Bio-Rad). In a series of control blots, the primary
antibodies were omitted or the goat antibody was pre-incubated
with blocking peptide (sc-18960P, Santa Cruz) to confirm the
specificity of the detected signals. Immunoblots were reprobed
with b-actin antibody (1:10000, mouse monoclonal antibody,
Sigma) for normalisation.
The blot signal intensity obtained for NrCAM was normalised
against the signal obtained for b-actin on the same western blot.
Protein levels were expressed as fold increase with respect to
normal paired thyroid tissues (¼1).
Statistical methods
Comparison of transcript levels in tumours and paired normal
tissues, and the association of NrCAM transcript level or
immunohistochemical expression with other tumour variables
were analysed using the Mann–Whitney U-test. A probability
value (P) of less than 0.05 was considered statistically significant.
RESULTS
Expression of NrCAM mRNA in cancerous and normal
thyroid tissues
Quantitative (real-time) RT–PCR was used to investigate NrCAM
expression in PTCs and paired normal tissues. In all cases, a single
amplicon of the expected size was detected (data not shown)
indicating that in both normal and cancerous thyroid tissues,
NrCAM was expressed. As shown in Figure 1A, the NrCAM mRNA
was clearly detected in both normal thyroid tissues and PTC
samples. Expression of the NrCAM transcript was significantly
higher (Po0.0001) in tumours (mean normalised expression
0.1270.05), than in normal thyroid (0.02170.019) (Figure 1B).
The tumour to paired normal tissue ratio of NrCAM mRNA levels
ranged from 1.3 to 30.7 (average 5.7). In 17 cases (37%), the
expression was at least twofold and in 22 cases (48%) fivefold to
30-fold greater in the tumour compared with the corresponding
normal tissue. The relative amount of NrCAM transcript was
significantly higher whatever the tumour stage or size (Figure 1C,
Table 1).
Although we observed differences in the relative amount of the
NrCAM mRNA between PTCs at different stages (highest levels
found in pT3/pT4N1), these were not statistically significant. There
was also no association between mRNA expression and regional
lymph node metastasis (data not shown).
The RET oncogene expression analysis by real-time RT–PCR
revealed the presence of rearrangements in 8 out of 46 analysed
samples (17.4%). Five cases (10.9%) were identified as RET/PTC1, and
the other three (6.5%) as RET/PTC3 – both classic variants of PTC.
NrCAM protein expression and cellular localisation
Neuron-glia-related cell-adhesion molecule expression and tissue
distribution were then evaluated by immunohistochemistry in
archived paraffin-embedded samples from 46 cases of papillary
carcinoma. The TNM staging, morphological subtyping of tumours
and immunohistochemical analyses of NrCAM are summarised in
Table 2. Representative immunostaining with specific anti-NrCAM
Table 2 NrCAM immunoreactivity in relation to papillary carcinomas
stage and variant
NrCAM immunostaining
T
Subtype
n¼53
Node
metastases
450%
(3+/2+)
11-50%
(2+/1+)
o10%
(1+) 0
FA (3) 3
AA (4) 4
T1 PTC (3) 2 1
FVPTC
T2 PTC (36) 1 18 12 5 1
FVPTC(4) 1 3
T3 PTC (1) 1
FVPTC(2) 1 1 1
Abbreviation: NrCAM¼neuron-glia-related cell-adhesion molecule; FA¼follicular
adenoma; AA¼atypical adenoma, PTC¼papillary thyroid carcinoma; FVPTC¼
follicular variants of papillary carcinoma.
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santibodies is shown in Figure 2C–H. Most of the PTCs analysed
(43/46) were positive for NrCAM expression, which was confined
to tumour cells. Nineteen (41%) showed only diffuse cytoplasmic
immunostaining, while 24 (52%) showed both cytoplasmic and
membranous (basal and apical) staining (Figure 2C–H). Further-
more, 85% (39/46) of PTC tumours displayed intense (2þ/3þ)
NrCAM immunoreactivity in 470% of cells. However, neither
tumour stage nor size was associated with the overexpression of
NrCAM (Figure 2C–H, Table 2). In follicular adenomas, focal
cytoplasmic and membranous staining was observed whereas
atypical adenomas were negative for NrCAM reactivity, Table 2.
The level of the NrCAM immunoreactivity was significantly
higher in PTCs than in adjacent normal thyroid tissue (Po0.0001).
The thyroid tissues next to and at a distance from the tumour were
largely unstained with the exception of focally stained cells in rare
follicles containing characteristic tall cells showing features of
hyperactivity (Figure 2A and 2A inset). In these follicles the
NrCAM staining was seen only at the apical membrane of the
thyrocytes. Negative controls were consistently free of immuno-
reactivity (Figure 2B). Peripheral nerves used as internal positive
controls showed intense NrCAM reactivity (Figure 2B inset).
Overall, the presence and level of NrCAM immunostaining closely
mirrored the specific mRNA abundance determined by QRT–PCR.
Western blotting
To corroborate the QRT–PCR and immunohistochemistry results
we carried out the western immunoblot analysis on 46 fresh PTC
tissue samples. As shown in Figure 3A, the intensity of the NrCAM
signal obtained with both specific antibodies was proportional to
the protein input. Polyclonal NrCAM antibodies directed against
either the extracellular or internal regions of the molecule detected
a band of approximately 200–220kDa on western blots of protein
extracts from both the PTC and paired normal thyroid tissues
(Figure 3A). In cancer samples, the intensity of the NrCAM protein
band varied between cases; however, the reactive protein level in
tumours was substantially higher than in normal thyroid tissues.
This pattern was seen in all examined tumour/normal thyroid
pairs. Representative western blot data for tumours and paired
samples are shown in Figure 3B. On average, the level of NrCAM
was 3.6-fold higher in PTC than in paired normal tissues (NT)
(Figure 3C). The NrCAM protein levels determined by western
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Figure 1 Expression of the NrCAM transcript in 46 PTCs analysed using quantitative RT–PCR. (A) Relative NrCAM mRNA expression in PTC (T) and
normal tissues (NT); (B) relative expression in each PTC/normal tissue pair; (C) relative expression in PTCs at different stages. NrCAM, b-actin and GAPDH
mRNA levels were quantified and NrCAM expression normalised against that of the two housekeeping genes. Each point represents the mean of duplicate
measurements obtained for each sample in the series. Mann–Whitney U-test analysis was carried out and the corresponding P value is presented.
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sblotting were consistent with those detected by immunohisto-
chemistry (IHC), which validated the finding that NrCAM is
overexpressed in human PTCs at both the mRNA and protein levels.
DISCUSSION
Tumour progression is a multistage process in which tumour
cells accumulate different abnormalities involving rearrangement,
induction, or silencing of the cell-adhesion molecules (Fidler, 2002;
Hirohashi and Kanai, 2003; Cavallaro and Christofori, 2004).
The neuronal cell-adhesion molecule NrCAM is mainly, but not
solely, expressed in the central and peripheral nervous system. It
has recently been reported that NrCAM is also expressed in a
variety of other tissues, endothelial cells, certain tumour cell lines,
and human cancers (Wang et al, 1998; Glienke et al, 2000;
Dhodapkar et al, 2001; Aitkenhead et al, 2002; Conacci-Sorrell
et al, 2002a). Here we present strong experimental evidence that
NrCAM expression is induced in PTCs. As shown by QRT–PCR,
NrCAM mRNA was present at higher levels in all PTC samples
than in normal thyroid tissues, and its overexpression occurs at
the transcriptional level. Because NrCAM overexpression was
seen in all examined cases, we assessed whether it could be
associated with tumour progression or metastasis. The NrCAM
upregulation was found in all PTCs so its presence was apparently
not related to their differentiation grade or stage. We did observe
that tumours with more aggressive clinical behaviour (eg, pT4N1)
tended to express higher levels of NrCAM, suggesting possible
involvement of this molecule in regional spread – a characteristic
feature of papillary carcinomas – but these differences were not
statistically significant. Therefore, it seems that the NrCAM
induction and upregulation in PTCs is also not related to nodal
metastasis.
Immunohistochemistry verified the QRT–PCR results at the
protein level. The immunostaining pattern of papillary tumours,
peritumoural, and normal thyroid tissues unequivocally demon-
strated that NrCAM is expressed by tumour cells and not merely
by nervous components of the thyroid gland. Our observation that
focal immunostaining was rare in the normal thyroid, while such
staining was common in tumours, indicated that elevated NrCAM
expression is specific for tumour cells and represents a true
tumour-associated abnormality. In the vast majority of PTCs,
NrCAM protein expression was high, as estimated by the intensity
of staining. Moreover, the changes in the level of expression
reflected by altered immunoreactivity were consistent with those
detected by QRT–PCR. Strong NrCAM immunolabelling was
found irrespective of the tumour stage or size, including clinically
quiescent micro-carcinomas.
Because primary tumours contain both cancer cells and a variety
of stroma cells, it was important to carefully examine the
localisation of the NrCAM protein. In normal thyroid, NrCAM
was detected only in rare follicles containing tall cells showing
features of hyperactivity, and in these cells the protein was located
exclusively at the apical pole of thyrocytes. In contrast, a diffuse
cytoplasmic pattern of NrCAM distribution was seen in all
analysed PTCs. In some tumours, membranous, both apical and
basal, NrCAM localisation was also observed.
The quantitative RT–PCR and IHC results were corroborated
by western blot analysis. In all cases, the levels of immunoreactive
NrCAM protein were higher in tumours than in normal paired
tissues. In summary, we found induction and overexpression of
NrCAM in tumours arising from cells that very rarely express this
cell-adhesion molecule in normal tissue.
The biological basis of NrCAM induction, overexpression,
intracellular, and basal localisation is as yet unclear. Four genetic
defects, at the somatic level, are associated with papillary cancers
of the thyroid: chromosomal recombination events affecting
RET and TRKA, and activating mutations of RAS and BRAF. The
RET and TRKA genes encode membrane tyrosine kinase receptors
for neural growth factors: RET is one of the receptors for glial cell
A
CDE
H G F
B
Figure 2 Representative immunostaining results obtained using anti-NrCAM antibodies (clone sc-18960, Santa Cruz) on sections of normal thyroid
tissues and PTCs. Controls: (A) normal thyroid was largely unstained with some focally stained follicles (A-inset); (B) strongly stained peripheral nerves as an
internal positive control (B-inset). PTCs: (C–H) Intense cytoplasmic and membranous staining of PTCs at different tumour stages (C-pT1, PTC with
follicular and papillary pattern growth, area with follicular architecture; D, E, F-pT2,G ,H - pT3, classic PTC with papillary pattern of growth). Original
magnifications: A  400, A inset  400; B  200, B inset  400; C–H  400.
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sline-derived neurotrophic factor, whereas TRKA is a receptor for
nerve growth factor (Klein et al, 1991; Airaksinen et al, 1999). One
of the mechanisms involved in NrCAM induction seems to be the
RET chromosomal rearrangement. Activation of the RET gene at
its chromosomal locus occurs in from about 20% to more than
40% of sporadic PTCs, including micro-carcinomas, and is thus an
early event in thyroid carcinogenesis (Nikiforov, 2002; Santoro
et al, 2004). It has recently been shown that artificially raised
expression of RET/PTC1 – one of two most prevalent RET/PTC
variants found in the vast majority of PTCs – in normal human
thyrocytes, directly induces many inflammatory and tumour-
invasion genes including the NrCAM gene (Borello et al, 2005). In
this study, we found similar NrCAM upregulation at both the
transcriptional and protein levels in a large number of PTC thyroid
samples. Thus, it is conceivable that in PTC cells, RET-derived
chimeras might trigger NrCAM induction and upregulation. In the
present study RET/PTC1 and RET/PTC3, the most frequent
rearrangements detected in papillary carcinomas, occurred with
a similar frequency: RET/PTC1 was present in five cases of PTC
(10.9%) and RET/PTC3 in three cases (6.5%). These frequencies
are similar to those reported previously (Santoro et al, 2002).
However, taking into account the high frequency of NrCAM
overexpression we observed, and the prevalence of RET/PTC, it
is likely that NrCAM induction in PTCs is an event only partly
dependent on the RET/PTC rearrangement, and other factors are
likely to be involved. The most common genetic abnormality
identified from 29 to 83% of PTCs is a somatic point mutation in
the BRAF gene leading to a V600E substitution (Xing, 2005). The
occurrence of the BRAF
V600E mutation is associated with particular
PTC histotypes, being much more common in the classic type of
PTCs than in FVPTC where another mutation, BRAFK601E, is
found with an overall frequency of up to 12% (Soares et al, 2003;
Trovisco et al, 2004, 2006; Xing, 2005). Among the PTCs examined
in the present study there were only four cases of the follicular
variant of PTC, and in these carcinomas the NrCAM transcript was
overexpressed in comparison with normal thyroid. In the series of
archived cases there were six FVPTCs, all showing NrCAM protein
overexpression. Although we did not analyse the BRAF
V600E
mutation, the fact that two-thirds of PTCs show this genetic
abnormality and in view of high prevalence of NrCAM mRNA
overexpression found in this series of PTCs (all cases), it may be
speculated that constitutive signalling along the RET–RAS–
BRAF–MAPK pathway may initiate NrCAM neoexpression in
PTCs. Further studies are required to determine the relationship
between PTC-associated genetic abnormalities and the induction
of NrCAM expression.
Many different cell-adhesion molecules are implicated in human
carcinogenesis. Neuronal cell-adhesion molecules act in cell
adhesion, although their effects are also linked with different
recognition processes and signal transduction pathways regulating
cell differentiation, proliferation, or migration (Gumbiner, 1996;
Cavallaro and Christofori, 2004). Several lines of evidence indicate
that expression of NrCAM and other members of the L1-CAM
family might be important in the biological behaviour of human
tumours (Wang et al, 1998; Dhodapkar et al, 2001; Fogel et al,
2003; Allory et al, 2005; Euer et al, 2005). Previous studies have
shown that NrCAM is a target gene of b-catenin signalling in
human melanoma, and colon carcinoma cell lines and tissues
(Conacci-Sorrell et al, 2002b). The induction of NrCAM transcrip-
tion by b-o rg-catenin plays a role in melanoma and colon
carcinogenesis, most likely by promoting cell growth and motility
(Conacci-Sorrell et al, 2002b). Furthermore, the NrCAM ectodo-
main was found to be shed from the cell surface, and could activate
various signalling pathways, enhance cell motility and confer
tumourigenesis in mice (Conacci-Sorrell et al, 2005). Moreover,
suppression of NrCAM expression by siRNA in melanoma cells
inhibited the adhesive and tumourigenic ability of these cells
(Conacci-Sorrell et al, 2005). Increased NrCAM levels were found
in well- or moderately differentiated pancreatic cancers, whereas
this protein was reduced or absent in most poorly differentiated
tumours, suggesting that differential NrCAM expression may be
involved in the pathogenesis and invasive/metastatic behaviour
of pancreatic tumours (Dhodapkar et al, 2001). Recently, the
neoexpression of the coreceptor of the active form of TRKA, p75
neurotrophin receptor (p75NTR), was demonstrated in a series of
PTCs in comparison with normal thyroid (Rocha et al, 2006). The
expression of this neuronal protein was found only in PTC,
especially in typical papillary carcinomas. Immunohistochemical
examination of p75NTR expression with analysis of BRAF
V600E in
typical PTCs did not show a significant correlation between this
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Figure 3 Immunoblotting of neuron-glia-related cell-adhesion molecule
(NrCAM). PTC and normal thyroid tissue protein extracts were subjected
to western blot analysis with antibodies against NrCAM (ab24344, Abcam)
or b-actin. (A) Semi-quantitative detection of NrCAM by western blotting.
Increasing amounts of pooled protein extracts prepared from 10 normal
and 10 papillary carcinoma thyroid tissue samples. Chemiluminescence
signals (inset) were scanned and quantified as reported in Materials and
Methods. Amounts of immunoreactive NrCAM, expressed as arbitrary
units, are plotted as a function of the amount of membrane protein loaded
in each lane. (B) Comparative analyses of NrCAM content of thyroid
tumours and paired normal thyroid samples. Protein extracts (50mg) from
each PTC and normal paired thyroid were subjected to western blot
analysis and chemiluminescence detection. b-Actin was then detected on
the same membranes and the signals used to normalise NrCAM values.
Paired samples were analysed simultaneously. Data from five representative
paired tumour/normal thyroid samples are shown. (C) Mean NrCAM
protein content in a series of PTCs and normal thyroid (7s.e.m.)
expressed as arbitrary units. T-papillary thyroid carcinoma; NT-paired
normal thyroid tissue.
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smutation and immunopositivity, although an association between
the presence of BRAF
V600E and apical protein localisation was
found. Despite the fact that we have no data concerning the
frequency of BRAF
V600E in the present series of tumours, NrCAM
transcript expression was significantly higher in every analysed
cancer. The relevance of increased NrCAM expression in PTCs is
unknown at present. Its induction and overexpression in tumour
cells regardless of the primary tumour stage suggests that this is an
early event during PTC development.
Our results support the suggestion that NrCAM is one of
the several adhesion molecules that are involved in thyroid
carcinogenesis (Brabant et al, 1995). However, further studies are
needed to fully investigate the role of the NrCAM in the biology of
thyroid epithelial papillary carcinomas.
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